Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 11/20 | 0.68 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.68 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.68 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22333508 | 0.93 | OXTR (0.77) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL22333526 | 0.90 | OXTR (0.73) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL29738351 | 0.88 | OXTR (0.89) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL14008026 | 0.86 | OXTR (0.73) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL22333525 | 0.85 | OXTR (0.73) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL25597280 | 0.84 | OXTR (0.79) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL15511961 | 0.84 | OXTR (0.88) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL22333507 | 0.84 | OXTR (0.89) | OXTRAVPR2AVPR1AAVPR1B | |
| Oxytocin SCHEMBL11275096 | 0.82 | OXTR (0.89) | OXTRAVPR2AVPR1AAVPR1B | |
| SCHEMBL15512310 | 0.82 | OXTR (0.86) | OXTRAVPR2AVPR1AAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255475-A1 | METABOLITE INSPIRED SELECTIVE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255475-A1 | METABOLITE INSPIRED SELECTIVE OXYTOCIN RECEPTOR AGONISTS | OXTR, AVPR2, AVPR1A | OXTR 1/4885AVPR2 2/4885AVPR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.